Maternal mortality in the United States is higher than in peer nations and has not decreased since 1990. Beyond mortality, severe maternal mortality impacts far too many women. Not only are these high rates alarming, but notable racial/ethnic and socioeconomic disparities exist. These inequities are highly regional, with women living in the rural southeast part of the United States, including the Mississippi Delta, having the highest rates of maternal mortality and morbidity. Unfortunately, these disparities have proven to be stubbornly resistant to interventions, necessitating an innovative multifaceted approach focused on community practice, building trust, and prioritizing patient voices. To meet this need, this proposal aims to establish the Mississippi Delta Research Center of Excellence for Maternal Health with the goal of addressing preventable maternal mortality, decreasing severe maternal morbidity, and promoting maternal health equity in partnership with the Mississippi Delta community. This patient-clinical linkages intervention study will evaluate the effectiveness of a multilevel and multisector communication and health literacy strategy to increase trust and engagement in postpartum healthcare among women in the Mississippi Delta, with a specific focus on Black women, their families, and their communities.
These research projects both have the overarching goal of partnering with the community to determine and meet the needs of pregnant and postpartum women in the Mississippi Delta and address the disparities within maternity health and health care outcomes.

开始日期2025-01-01

申办/合作机构

Jackson State University

[+2]

NCT06472206 / RecruitingN/AIIT

Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)

Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH). These gaps are particularly prominent in the Deep South of the United States (US), where PWH face challenges in accessing healthcare services. In response, a team of experienced researchers has developed and tested the Community Health Workers And MHealth to ImProve Viral Suppression (CHAMPS) intervention. This intervention uses mobile health (mHealth) technology and a team of community health workers (CHW) to design an intervention to improve ART adherence and VS. The CHAMPS+ intervention adds a CHW delivered supportive risk reduction counseling during periods of non-suppression to prevent HIV transmission. The study will engage the participants by developing culturally relevant materials and retention strategies, evaluating the clinical effectiveness and sustainability of the intervention in Deep South settings, and assessing regionalized implementation factors. Ultimately, the study will test the effectiveness of CHAMPS+ on ART adherence and viral load suppression for PWH in Alabama, Louisiana, and Mississippi.

开始日期2024-11-23

申办/合作机构

Columbia University

[+5]

NCT05843903 / Not yet recruitingN/AIIT

Teen Mom Study Feasibility Trial: A Multicomponent Digital Health Intervention to Improve Cardiometabolic Health in Pregnant Black Adolescents

The proposed multicomponent digital health intervention has the potential to significantly impact the trajectory of maternal health in a rural, pregnant, Black adolescent population with the highest risks for cardiometabolic diseases worldwide. The proposed implementation strategy leverages mobile technologies which are ubiquitous across the socioeconomic gradient and proposes to train young adult WIC moms to deliver peer health coaching in a telehealth setting to address social barriers and support behavior change in pregnant, Black adolescent WIC clients in the Mississippi Delta - a rural region where the population is more than two-thirds percent Black and the teen birth rate is the highest in the United States. This is a scalable and sustainable approach to enhance WIC services and improve WIC's impact on population health and cardiometabolic health disparities in Black women.

开始日期2024-10-01

申办/合作机构

University of Mississippi Medical Center

[+3]

100 项与 University of Mississippi 相关的临床结果

登录后查看更多信息

0 项与 University of Mississippi 相关的专利（医药）

登录后查看更多信息

23,371

项与 University of Mississippi 相关的文献（医药）

2025-01-01·HEART & LUNG

Understanding attendance patterns and determinants in cardiac, pulmonary, and ICU rehabilitation/recovery programs: A systematic review and meta-analysis

Review

作者: Boehm, Leanne M. ; McPeake, Joanne ; Su, Han ; Shaw, Martin ; Jones, Abigail C ; Butler, Javed ; Eaton, Tammy L. ; Walden, Rachel Lane ; Boethel, Carl ; Eaton, Tammy L ; Jones, Abigail C. ; Renard, Valerie ; Potter, Kelly ; Boehm, Leanne M ; Danesh, Valerie

BACKGROUND:

Cardiac, pulmonary, and intensive care unit (ICU) rehabilitation/recovery programs are health promotion interventions designed to improve physical recovery, psychological well-being, and quality of life after acute illness while reducing the risk of adverse events.

OBJECTIVE:

Identify the difference in attendance rates for patients invited to a cardiac rehabilitation, pulmonary rehabilitation, or ICU recovery program and factors influencing attendance.

METHODS:

We conducted a systematic review and meta-analysis by searching PubMed, EMBASE, CINAHL, Web of Science, and manual reference lists from inception to June 3, 2024. We included studies reporting patient attendance rates in eligible programs following acute illness hospitalization. Two team members independently screened articles and extracted data, with a third member reviewing and achieving consensus when necessary. Our main outcomes focused on the proportion of attendance in eligible programs among patients referred.

RESULTS:

Of 3,446 studies screened, 179 studies (N = 4,779,012 patients) were included across cardiac rehabilitation (n = 153 studies), pulmonary rehabilitation (n = 11 studies), and ICU recovery (n = 15 studies) programs. Pooled attendance rates were 53 % (95 % CI: 48-57 %) for cardiac rehabilitation, 56 % (95 % CI: 42-70 %) for pulmonary rehabilitation, and 61 % (95 % CI: 51-70 %) for ICU recovery programs. Significant attendance heterogeneity was present (cardiac I²=100 %, p < 0.001; pulmonary I²=100 %, p < 0.001; ICU I²=94 %, p < 0.01). Barriers to attendance included transportation, distance, work conflicts, and patient factors (e.g., comorbidities, older age). Facilitators included male gender, younger age, higher education, income, provider recommendations, and flexible scheduling. Individual factors represented the primary domain affecting attendance.

CONCLUSIONS:

The results indicate comparable attendance rates and factors shaping attendance across acute illness rehabilitation/recovery programs, with ICU recovery programs being the most well-attended on average.

REGISTRATION:

PROSPERO CRD42022357261.

2024-12-31·The Journal of dermatological treatment

Topical clindamycin for acne vulgaris: analysis of gastrointestinal events

Review

作者: Pelet Del Toro, Natalia M ; Han, George ; Stein Gold, Linda ; Wu, Jashin J ; Strunk, Andrew ; Brodell, Robert T ; Del Rosso, James Q

Purpose: Topical clindamycin, a lincosamide antibiotic, is commonly combined with benzoyl peroxide or a retinoid for acne vulgaris (AV) treatment. While oral and topical clindamycin carry warnings/contraindications regarding gastrointestinal (GI) adverse events (AEs), real-world incidence of GI AEs with topical clindamycin is unknown. This review provides background information and an overview of safety data of topical clindamycin for treating AV.Materials and Methods: Available safety data from published literature, previously unpublished worldwide pharmacovigilance data, and two retrospective cohort studies were reviewed.Results and Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data and limited generalizability. This review of published case reports, worldwide pharmacovigilance data, retrospective US prescription data, and clinical trials safety data demonstrates that the incidence of colitis in patients exposed to topical clindamycin is extremely low.

2024-12-31·Human vaccines & immunotherapeutics

Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection

Article

作者: Burnett, Grace C ; Seyfarth, Kristina B ; Ederer, Dallas R ; Montgomery, Denise D ; Marshall, Gailen D ; Bierdeman, Michael A ; Pham, Amanda T ; Lirette, Seth T ; Farmer, Andrew P ; Bates, John T

Virus-neutralizing antibodies are often accepted as a correlate of protection against infection, though questions remain about which components of the immune response protect against SARS-CoV-2 infection. In this small observational study, we longitudinally measured spike receptor binding domain (RBD)-specific and nucleocapsid (NP)-specific serum IgG in a human cohort immunized with the Pfizer BNT162b2 vaccine. NP is not encoded in the vaccine, so an NP-specific response is serological evidence of natural infection. A greater than fourfold increase in NP-specific antibodies was used as the serological marker of infection. Using the RBD-specific IgG titers prior to seroconversion for NP, we calculated a protective threshold for RBD-specific IgG. On average, the RBD-specific IgG response wanes below the protective threshold 169 days following vaccination. Many participants without a history of a positive test result for SARS-CoV-2 infection seroconverted for NP-specific IgG. As a group, participants who seroconverted for NP-specific IgG had significantly higher levels of RBD-specific IgG following NP-seroconversion. RBD-specific IgG titers may serve as one correlate of protection against SARS-CoV-2 infection. These titers wane below the proposed protective threshold approximately six months following immunization. Based on serological evidence of infection, the frequency of breakthrough infections and consequently the level of SARS-CoV-2-specific immunity in the population may be higher than what is predicted based on the frequency of documented infections.

项与 University of Mississippi 相关的新闻（医药）

2024-09-17

·PRNewswire

The Inner Circle acknowledges, Lee C. Ferguson, DO, FACS as a Pinnacle Lifetime Member

MOBILE, Ala., Sept. 16, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lee C. Ferguson, DO, FACS is acknowledged as a Pinnacle Lifetime Member for his contributions as a Vascular Surgeon. Continue Reading Lee Ferguson Dr. Ferguson, a distinguished dual board-certified vascular surgeon and endovascular specialist, has been transforming vascular care in Mobile, Alabama, and its surrounding regions. He is a key member of Vascular Associates of South Alabama, LLC, renowned for his expertise in advanced, minimally invasive, endovascular techniques and traditional open surgery. Dr. Ferguson's unwavering commitment to patient-centered care reflects his belief in treating each patient as he would want his own family to be treated. His practice covers a wide spectrum of vascular conditions, including peripheral arterial disease, limb salvage, aortic aneurysms, carotid disease, varicose veins, and more. With years of dedication to the field of medicine, Dr. Ferguson holds a distinguished educational background, including a Bachelor of Science in Biology from the University of Arkansas at Monticello and a Doctor of Osteopathic Medicine (DO) from Pikeville College of Osteopathic Medicine. His training includes a general surgical residency at the University of South Alabama in Mobile and a fellowship in vascular surgery at the University of Mississippi Medical Center in Jackson. As a testament to his expertise, Dr. Ferguson is dual board-certified in vascular surgery and general surgery, a Diplomat to the American College of Surgeons (ACS), and a Fellow of the American College of Surgeons (FACS). He is also a Registered Physician in Vascular Interpretation (RPVI) and holds certifications in Advanced Cardiac Life Support (ACLS) and Basic Life Support (BLS). Dr. Ferguson's commitment extends beyond his practice, as he actively engages with professional organizations and medical societies, including the Alabama Medical Society, Mobile County Medical Society, American College of Surgeons, and Society of Vascular Surgeons. He shares his knowledge as a presenter at various medical conferences and co-authored a poster presentation for The Southeastern Surgical Congress meeting in 2013. Outside of medicine, Dr. Ferguson finds solace in the great outdoors. He enjoys hunting, fishing (both inshore and offshore), and sporting clays. His dedication to community service shines through his involvement with his local Mardi Gras Association, the Broad Street Restoration Society, and his role as a Mobile City Police Surgeon, where he volunteers his services for the local law enforcement community. Dr. Ferguson's family is a pillar of support, with his wife, Mrs. Kim Ferguson, and their two teenagers standing by his side. As a leading figure in vascular surgery, Dr. Ferguson's commitment to excellence in patient care and his contributions to the medical field continue to elevate the standard of vascular care in Mobile, Alabama, and the surrounding areas. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2024-08-27

·Business Wire

Cayuga Biotech Announces That PolyP-SNP Complex Data Demonstrate Potential to Address Top Causes of Death from Hemorrhage After Battlefield Injury

NEW YORK--( BUSINESS WIRE )--Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to heal and stop bleeding, today presented preclinical data on its first generation, first-in-class, polyphosphate (polyP)-based therapy designed to address life-threatening hemorrhage. The results demonstrated that the infused polyP-SNP (silica nanoparticle) complex was able to overcome conditions known to be associated with poor survival after injury with hemorrhage, known as the “lethal triad”—hemodilution, acidemia, and hypothermia. These data were presented as a poster presentation at the Military Health System Research Symposium in Kissimmee, FL. “Bleeding is the leading cause of preventable death after traumatic injury in the battlefield, in large part due to the difficulty in treating non-compressible hemorrhage, such as from penetrating injury,” said Charles Pollack, MD, emergency medicine physician at the University of Mississippi and previously, Regimental Surgeon, 4 th Marines, US Navy Medical Corps. “These data are exciting because this novel polyP-SNP complex can overcome some of the most challenging clinical conditions to help restore the ability to clot.” Data presented in the “Technologies for the Treatment of Battlefield Hemorrhage and Management of Vascular Dysfunction” session demonstrated normalized thrombin generation and clotting under extreme hemodilute conditions in which normal plasma failed. Improved coagulation was also observed under severe acidotic and hypothermic conditions. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response without driving excess clotting, a problem that has limited development for other injectable drugs to treat hemorrhage. Poster Session 1: “A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions” About Hemorrhage Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death. About Cayuga Biotech, Inc. Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com .

临床结果

2024-07-25

·PRNewswire

The Caris Precision Oncology Alliance Welcomes The University of Mississippi Medical Center

Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by welcoming the University of Mississippi Medical Center IRVING, Texas, July 25, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that The University of Mississippi Medical Center (UMMC) has joined the Caris Precision Oncology Alliance™ (Caris POA). Continue Reading The Caris POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris' highly sophisticated AI bioinformatics and machine learning capabilities across Caris' massive multi-modal database to enable innovative research to improve clinical outcomes for cancer patients. Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes Post this The University of Mississippi Medical Center is the state's only academic medical center, with a focus to improve the health of Mississippi's population and eliminate health disparities through education, research and patient care. Their three-part mission is to improve the lives of Mississippians by educating tomorrow's health care professionals, conducting health sciences research, and providing cutting-edge patient care. UMMC encompasses six health science schools of medicine, nursing, health related professions, dentistry, graduate studies and population health. "We are pleased to welcome the University of Mississippi Medical Center into the growing Caris Precision Oncology Alliance," said George W. Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. "UMMC's commitment to cutting-edge therapy, clinical trials and interdisciplinary collaboration makes them a valuable alliance member. We're eager to collaborate with their investigators on our shared mission of improving the outcomes of all patients affected by cancer." "The power of the Caris POA is that it provides UMMC access to not only thousands of complete annotations and molecular profiling data points for each patient, but also a network of investigators and oncologists, both of which are powerful resources for cancer researchers," said Rodney Rocconi, MD, FACOG, director of the UMMC Cancer Center and Research Institute and Ergon Chair for Cancer Research. "This cutting-edge data will provide our physicians with immediate information at their fingertips." The Caris POA includes 95 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to one of the largest and most comprehensive multi-modal databases in the industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering tens of billions of datapoints per patient. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com. About the University of Mississippi Medical Center As the state's only academic medical center, UMMC seeks to improve the health of Mississippi's population and eliminate health disparities through education, research and patient care. UMMC encompasses six health science schools of medicine, nursing, health related professions, dentistry, graduate studies and population health. The Medical Center includes the state's only Level I trauma center, only children's hospital, only organ and bone marrow transplant program and the only Telehealth Center of Excellence, one of two in the nation. For more information, visit . Caris Life Sciences Media Contact: Lisa Burgner [email protected] 214.294.5606 University of Mississippi Medical Center Media Contact: Jewell Davis, PhD, MS [email protected] 601.815.5718 SOURCE Caris Life Sciences

临床研究

100 项与 University of Mississippi 相关的药物交易

登录后查看更多信息

100 项与 University of Mississippi 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

PDC-APB	皮炎更多	临床1期
Artemisinin analogues(University of Mississippi)	疟疾更多	临床前
ELP-P10 ( HCMV gp )	巨细胞病毒感染更多	临床前
Suvadronabinol ( CB1 )	青光眼更多	临床前
18F-FTC-146 ( σ1 receptor )	坐骨神经痛更多	无进展